Published in Expert Opin Biol Ther on March 01, 2009
The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol (2011) 4.18
Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens. Biochem Biophys Res Commun (2009) 3.38
Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. J Virol (2014) 1.52
Monoclonal antibody-based therapies for microbial diseases. Vaccine (2009) 1.47
Rhabdovirus-based vaccine platforms against henipaviruses. J Virol (2014) 0.84
Evaluation of two magnetic-bead-based viral nucleic acid purification kits and three real-time reverse transcription-PCR reagent systems in two TaqMan assays for equine arteritis virus detection in semen. J Clin Microbiol (2011) 0.82
A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med (2003) 29.55
Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med (2003) 27.97
Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet (2003) 24.78
Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature (1998) 24.69
Bats are natural reservoirs of SARS-like coronaviruses. Science (2005) 13.44
Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature (2007) 11.73
Nipah virus: a recently emergent deadly paramyxovirus. Science (2000) 9.39
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature (2003) 8.77
Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci U S A (2005) 8.52
A morbillivirus that caused fatal disease in horses and humans. Science (1995) 7.61
Fatal encephalitis due to Nipah virus among pig-farmers in Malaysia. Lancet (1999) 5.14
Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science (2005) 4.97
An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med (2004) 4.89
A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature (2004) 3.90
Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J Virol (2004) 3.76
A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J Biol Chem (2003) 3.60
EphrinB2 is the entry receptor for Nipah virus, an emergent deadly paramyxovirus. Nature (2005) 3.39
Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci U S A (2004) 3.23
Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus. Proc Natl Acad Sci U S A (2005) 3.18
Clinical features of Nipah virus encephalitis among pig farmers in Malaysia. N Engl J Med (2000) 3.12
Hendra and Nipah viruses: different and dangerous. Nat Rev Microbiol (2006) 2.95
Passive antibody therapy for infectious diseases. Nat Rev Microbiol (2004) 2.64
Structural basis of Nipah and Hendra virus attachment to their cell-surface receptor ephrin-B2. Nat Struct Mol Biol (2008) 2.58
Virus entry: molecular mechanisms and biomedical applications. Nat Rev Microbiol (2004) 2.51
Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci U S A (2004) 2.38
The SARS-CoV S glycoprotein: expression and functional characterization. Biochem Biophys Res Commun (2003) 2.23
Update: outbreak of Nipah virus--Malaysia and Singapore, 1999. MMWR Morb Mortal Wkly Rep (1999) 2.13
Nipah virus: vaccination and passive protection studies in a hamster model. J Virol (2004) 2.09
Host cell recognition by the henipaviruses: crystal structures of the Nipah G attachment glycoprotein and its complex with ephrin-B3. Proc Natl Acad Sci U S A (2008) 2.08
Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies. J Virol (2006) 2.00
Neutralization assays for differential henipavirus serology using Bio-Plex protein array systems. J Virol Methods (2007) 1.99
Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys. Virology (2004) 1.91
Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody. J Biol Chem (2006) 1.90
Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus. J Virol (2005) 1.89
Return to the past: the case for antibody-based therapies in infectious diseases. Clin Infect Dis (1995) 1.86
Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med (1989) 1.85
S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients. J Virol (2004) 1.80
Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. J Mol Biol (2005) 1.80
Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Natl Acad Sci U S A (2007) 1.76
Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters. J Virol (2005) 1.75
Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. Proc Natl Acad Sci U S A (2005) 1.75
Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J Immunol (2005) 1.70
Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet (2004) 1.70
Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc Natl Acad Sci U S A (2004) 1.69
SARS-associated coronavirus. N Engl J Med (2003) 1.69
Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem Biophys Res Commun (2004) 1.67
Treatment of West Nile virus encephalitis with intravenous immunoglobulin. Emerg Infect Dis (2001) 1.56
Antibodies for the prevention and treatment of viral diseases. Antiviral Res (2000) 1.56
Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants. J Virol (2005) 1.54
Structural basis of neutralization by a human anti-severe acute respiratory syndrome spike protein antibody, 80R. J Biol Chem (2006) 1.53
Treatment of severe acute respiratory syndrome with convalescent plasma. Hong Kong Med J (2003) 1.51
Importance of dose of neutralising antibodies in treatment of Argentine haemorrhagic fever with immune plasma. Lancet (1984) 1.51
Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection. J Infect Dis (2004) 1.50
Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet (2003) 1.49
Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody. J Infect Dis (2008) 1.48
Antibody prophylaxis and therapy against Nipah virus infection in hamsters. J Virol (2006) 1.47
Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice. J Infect Dis (2005) 1.44
Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrob Agents Chemother (1994) 1.41
Susceptibility of pigs and chickens to SARS coronavirus. Emerg Infect Dis (2004) 1.35
Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med (2006) 1.34
Possible benefit of intravenous immunoglobulin therapy in a lung transplant recipient with West Nile virus encephalitis. Transpl Infect Dis (2002) 1.34
Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies. J Virol (2004) 1.32
SARS corona virus peptides recognized by antibodies in the sera of convalescent cases. Virology (2004) 1.29
Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J Virol (2004) 1.28
Risk factors for Nipah virus infection among abattoir workers in Singapore. J Infect Dis (2000) 1.23
Introduction to Current focus on Hendra and Nipah viruses. Microbes Infect (2001) 1.20
An exposed domain in the severe acute respiratory syndrome coronavirus spike protein induces neutralizing antibodies. J Virol (2004) 1.18
Development of a safe neutralization assay for SARS-CoV and characterization of S-glycoprotein. Virology (2004) 1.17
Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era? Trends Pharmacol Sci (2004) 1.13
Preventing infectious disease with passive immunization. Microbes Infect (2000) 1.12
Nipah viral encephalitis or Japanese encephalitis? MR findings in a new zoonotic disease. AJNR Am J Neuroradiol (2000) 1.11
Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection. Pediatr Infect Dis J (2004) 1.11
A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice. Int Immunol (2004) 1.10
Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry. Biochem Biophys Res Commun (2004) 1.10
Passive antibody therapies: progress and continuing challenges. Clin Immunol (1999) 1.09
The neurological manifestations of Nipah virus encephalitis, a novel paramyxovirus. Ann Neurol (1999) 1.09
Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines. J Immunol (2004) 1.09
Passive immunization for the prevention and treatment of HIV infection. AIDS (1992) 1.08
Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus. J Virol (2005) 1.08
Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines. Virology (2005) 1.04
Lassa immune serum. Bull World Health Organ (1977) 1.04
Single amino acid substitutions in the severe acute respiratory syndrome coronavirus spike glycoprotein determine viral entry and immunogenicity of a major neutralizing domain. J Virol (2005) 1.03
Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice. DNA Cell Biol (2004) 1.02
The SARS coronavirus S glycoprotein receptor binding domain: fine mapping and functional characterization. Virol J (2005) 1.00
Antibody responses against SARS-coronavirus and its nucleocaspid in SARS patients. J Clin Virol (2004) 0.99
Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus. J Virol Methods (2004) 0.99
Phase I/II trial of HIV-1 hyperimmune globulin for the prevention of HIV-1 vertical transmission in Uganda. AIDS (2002) 0.98
Chronic pure red cell aplasia caused by parvovirus B19 in AIDS: use of intravenous immunoglobulin--a report of eight patients. Am J Hematol (1999) 0.97
High mortality in Nipah encephalitis is associated with presence of virus in cerebrospinal fluid. Ann Neurol (2000) 0.97
Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus. Clin Microbiol Infect (2004) 0.96
Passive immunotherapy in AIDS: a double-blind randomized study based on transfusions of plasma rich in anti-human immunodeficiency virus 1 antibodies vs. transfusions of seronegative plasma. Proc Natl Acad Sci U S A (1995) 0.95
Characterization of humoral responses in mice immunized with plasmid DNAs encoding SARS-CoV spike gene fragments. Biochem Biophys Res Commun (2004) 0.93
Parvovirus B19 infection-related complications in renal transplant recipients: treatment with intravenous immunoglobulin. Transplantation (1997) 0.93
Immunogenicity of SARS inactivated vaccine in BALB/c mice. Immunol Lett (2004) 0.92
Successful intravenous immunoglobulin therapy in 3 cases of parvovirus B19-associated chronic fatigue syndrome. Clin Infect Dis (2003) 0.91
Developments towards effective treatments for Nipah and Hendra virus infection. Expert Rev Anti Infect Ther (2006) 0.90
Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice. Vaccine (2005) 0.90
SARS vaccine development. Emerg Infect Dis (2005) 0.90
Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature (2007) 11.73
Evaluation of gene expression measurements from commercial microarray platforms. Nucleic Acids Res (2003) 8.08
Structure of a V3-containing HIV-1 gp120 core. Science (2005) 7.69
Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. Proc Natl Acad Sci U S A (2004) 5.15
Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol (2003) 4.49
Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science (2009) 4.20
Mammalian defensins in immunity: more than just microbicidal. Trends Immunol (2002) 3.52
Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens. Biochem Biophys Res Commun (2009) 3.38
Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus. Proc Natl Acad Sci U S A (2005) 3.18
Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature (2013) 3.14
Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc Natl Acad Sci U S A (2002) 3.08
Hendra and Nipah viruses: different and dangerous. Nat Rev Microbiol (2006) 2.95
Multiple roles of antimicrobial defensins, cathelicidins, and eosinophil-derived neurotoxin in host defense. Annu Rev Immunol (2004) 2.72
Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood (2012) 2.52
Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. Virology (2008) 2.37
Comparative analysis of bat genomes provides insight into the evolution of flight and immunity. Science (2012) 2.29
The SARS-CoV S glycoprotein: expression and functional characterization. Biochem Biophys Res Commun (2003) 2.23
Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4⁺ T cells to T-regulatory cells. Cancer Res (2011) 2.11
A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection. PLoS Pathog (2009) 2.09
Host cell recognition by the henipaviruses: crystal structures of the Nipah G attachment glycoprotein and its complex with ephrin-B3. Proc Natl Acad Sci U S A (2008) 2.08
Crystal structure of the broadly cross-reactive HIV-1-neutralizing Fab X5 and fine mapping of its epitope. Biochemistry (2004) 2.01
Thiol/disulfide exchange is a prerequisite for CXCR4-tropic HIV-1 envelope-mediated T-cell fusion during viral entry. Blood (2003) 2.00
Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies. J Virol (2006) 2.00
Neutralization assays for differential henipavirus serology using Bio-Plex protein array systems. J Virol Methods (2007) 1.99
Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody. J Biol Chem (2006) 1.90
Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus. J Virol (2005) 1.89
Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab selected by sequential antigen panning of a phage display library. J Immunol Methods (2003) 1.87
Feline model of acute nipah virus infection and protection with a soluble glycoprotein-based subunit vaccine. J Virol (2006) 1.87
Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. J Clin Invest (2005) 1.82
Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody. J Virol (2004) 1.80
Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates. J Virol (2002) 1.79
Regulation of human immunodeficiency virus type 1 envelope glycoprotein fusion by a membrane-interactive domain in the gp41 cytoplasmic tail. J Virol (2005) 1.76
Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Natl Acad Sci U S A (2007) 1.76
Filamin-A regulates actin-dependent clustering of HIV receptors. Nat Cell Biol (2007) 1.71
Membrane fusion tropism and heterotypic functional activities of the Nipah virus and Hendra virus envelope glycoproteins. J Virol (2002) 1.69
Vertical transmission and fetal replication of Nipah virus in an experimentally infected cat. J Infect Dis (2007) 1.68
Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells. Cancer Res (2009) 1.64
Identification of Hendra virus G glycoprotein residues that are critical for receptor binding. J Virol (2007) 1.61
Improved breadth and potency of an HIV-1-neutralizing human single-chain antibody by random mutagenesis and sequential antigen panning. J Mol Biol (2004) 1.61
Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration. Biochem Biophys Res Commun (2006) 1.58
Development of an acute and highly pathogenic nonhuman primate model of Nipah virus infection. PLoS One (2010) 1.54
Inhibitors of protein-disulfide isomerase prevent cleavage of disulfide bonds in receptor-bound glycoprotein 120 and prevent HIV-1 entry. J Biol Chem (2002) 1.54
Maturation Pathways of Cross-Reactive HIV-1 Neutralizing Antibodies. Viruses (2009) 1.54
Antibodies to Nipah or Nipah-like viruses in bats, China. Emerg Infect Dis (2008) 1.53
Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proc Natl Acad Sci U S A (2013) 1.51
Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization. Proc Natl Acad Sci U S A (2007) 1.50
Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers. Proc Natl Acad Sci U S A (2008) 1.49
Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody. J Infect Dis (2008) 1.48
Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function. Mol Cancer Ther (2006) 1.43
Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy. PLoS One (2008) 1.42
A recombinant subunit vaccine formulation protects against lethal Nipah virus challenge in cats. Vaccine (2008) 1.41
Wnt5A regulates expression of tumor-associated antigens in melanoma via changes in signal transducers and activators of transcription 3 phosphorylation. Cancer Res (2008) 1.41
Residues in the stalk domain of the hendra virus g glycoprotein modulate conformational changes associated with receptor binding. J Virol (2008) 1.40
A recombinant Hendra virus G glycoprotein-based subunit vaccine protects ferrets from lethal Hendra virus challenge. Vaccine (2011) 1.39
Human peripheral blood T regulatory cells (Tregs), functionally primed CCR4+ Tregs and unprimed CCR4- Tregs, regulate effector T cells using FasL. J Immunol (2007) 1.38
Improved titanium dioxide enrichment of phosphopeptides from HeLa cells and high confident phosphopeptide identification by cross-validation of MS/MS and MS/MS/MS spectra. J Proteome Res (2007) 1.37
A neutralizing human monoclonal antibody protects african green monkeys from hendra virus challenge. Sci Transl Med (2011) 1.35
DNA vaccines encoding human immunodeficiency virus-1 glycoprotein 120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses. Blood (2002) 1.30
Quantitative analysis of Nipah virus proteins released as virus-like particles reveals central role for the matrix protein. Virol J (2007) 1.30
Thymic stromal lymphopoietin is a key mediator of breast cancer progression. J Immunol (2011) 1.30
Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies. J Virol (2011) 1.26
Construction of a large phage-displayed human antibody domain library with a scaffold based on a newly identified highly soluble, stable heavy chain variable domain. J Mol Biol (2008) 1.25
Construction of a large naïve human phage-displayed Fab library through one-step cloning. Methods Mol Biol (2009) 1.23
Engineered human antibody constant domains with increased stability. J Biol Chem (2009) 1.22